Delay for Reloxin Release
The soon to be Botox rival ? Reloxin ? has yet to receive FDA marketing approval. The release date has been delayed due to issues in branding, labelling and marketing. The delay should only be a matter of weeks as officials are discussing the new anti-aging treatment's forthcoming strategy. According to Bloomberg, "Reloxin may be priced 15 percent lower than Botox, helping it take almost a third of the market over time, said Gary Nachman, an analyst at Leerink Swann & Co. in New York, in a phone interview last month. He estimates annual sales of Reloxin will be $160 million by 2012. Nachman and other analysts have said they expected the FDA to delay Reloxin approval until later this year over questions about how the company plans to track use in order to minimize potential risks seen with other botulinum toxins. Yesterday was a deadline for the FDA to make a decision on Reloxin." Reloxin is dubbed the next best thing for cosmetic dermatology, and may in fact be a competitive rival to the longstanding Botox. However, some specialists are wary and sceptical of its possible success, because many believe Botox has too dominant of a stamp in wrinkle-smoothing. Users are devoted to Botox and usually fearful of new procedures.